More Hong Kong patients suffering from spinal muscular atrophy (SMA) will be able to enjoy a government subsidy to control ...

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Provided by GlobeNewswire Jun 27, 2025, 2:00:23 PM ...

Findings from an Italian cohort suggest that nusinersen may benefit fatigue measures in patients with spinal muscular atrophy (SMA) type III; however, drawing definitive conclusions in this area ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates ...

Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to ...

--Ionis Pharmaceuticals today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA ® in infants and toddlers living with spinal muscular atrophy.

Across the 18 patients with SMA1, nusinersen resulted in a significant reduction in CSF levels of some, though not all, of the neuroinflammatory molecules that were increased at baseline.

A positive effect of nusinersen treatment on motor function in ambulant pediatric and adult spinal muscular atrophy (SMA) patients during a 38-month period has been demonstrated by an analysis of ...

Treatment with nusinersen was linked to increased motor function and reduction of the neurodegenerative biomarker neurofilament light chain in children with spinal muscular atrophy, according to ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 ...